Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (17213)	10/19/1998 12:58:00 PM
From: Logistics	Respond to of 120523

NSCP - I like it here. Any thoughts? JL

To: Jenna who wrote (17213)	10/19/1998 1:14:00 PM
From: Jeff Jordan	Read Replies (1) \| Respond to of 120523

Doing Well ... PECX+ 3 1/8 100.00%at6 1/4 CIEN+ 3 3/16 34.23%at12 1/2 ESST+ 9/16 24.32%at2 7/8 NTPA+ 15/16 22.06%at5 3/16 PSQL+ 1 1/4 19.23%at7 3/4 ADSK 26 1/22 5/8 10.99% 10/19/98 11:38 am... PHOTOELECTRON (PE1/2) UP 2-3/8, GETS FIRST ORDER FOR ITS PRS400 PROPRIETARY X-RAY DELIVERY SYSTEM FOR TUMOR THERAPY... NEEDHAM RATES BUY... Analyst Joe Bossong tells MarketScope this significant milestone for co... Notes co. received FDA clearance on PRS400 in first week of Aug., this first significant order in U.S, intl since U.S. approval... Thinks PRoffers unique means to deliver radiation to solid tumors... FDA has cleared device for primary, metastatic brain tumors... Will be reviewing earnings model over next week... Has $12 target over next year or so./J.Freund